Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group.

@article{Abraham1998DoubleblindRC,
  title={Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group.},
  author={Edward Abraham and Antonio Anzueto and Guillermo Guti{\'e}rrez and Sidney Tessler and Gerry S San Pedro and Richard G Wunderink and A R Dal Nogare and Stanley A. Nasraway and Stephen Berman and R Marty Cooney and Howard I Levy and R H Baughman and Mark J. Rumbak and Richard B. Light and Lona Poole and Randy Allred and Jean-François Constant and Jason Pennington and Stephen S. Porter},
  journal={Lancet},
  year={1998},
  volume={351 9107},
  pages={929-33}
}
BACKGROUND Despite the availability of potent antibiotics and intensive care, mortality rates from septic shock are 40-70%. We assessed the safety and efficacy of murine monoclonal antibody to human tumour necrosis factor alpha (TNF alpha MAb) in the treatment of septic shock. METHODS In a randomised, multicentre, double-blind, placebo-controlled clinical trial in 105 hospitals in the USA and Canada, we randomly assigned 1879 patients a single infusion of 7.5 mg/kg TNF alpha MAb (n=949) or… CONTINUE READING
168 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 168 extracted citations

Similar Papers

Loading similar papers…